Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment
Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of early symptomatic Alzheimer’s disease (AD). The trial showed that donanemab slowed cognitive and functional decline in patients with AD.
The results were announced at the 2023 Alzheimer’s Association International Conference (AAIC) as well as being published in the Journal of the American Medical Association (JAMA).
The company previously announced that the drug met all primary and cognitive and functional secondary endpoints in the phase 3 study.
Anne White, executive vice president of Eli Lilly and president of Lilly Neuroscience, commented: “The positive TRAILBLAZER-ALZ 2 data bring hope to people with AD who urgently need new treatment options. This is the first phase 3 study of a disease-modifying therapy to replicate the positive clinical results observed in a previous study. If approved, we believe donanemab can provide clinically meaningful benefits for people with this disease and the possibility of completing their course of treatment as early as six months once their amyloid plaque is cleared. We must continue to remove any barriers in access to amyloid-targeting therapies and diagnostics in an already complex healthcare ecosystem for AD.”
Mark Mintun, MD, group vice president of Neuroscience Research and Development at Lilly, added: “People living with early, symptomatic AD are still working, enjoying trips, sharing quality time with family – they want to feel like themselves, for longer. The results of this study reinforce the importance of diagnosing and treating disease sooner than we do today.”
NMD Pharma has announced that the first patient has been dosed in its phase 2 …
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …